Adaptimmune Therapeutics (ADAP) News Today $1.09 -0.02 (-1.80%) (As of 09/6/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 Time Period August 29, 2024 | finanznachrichten.deAdaptimmune Therapeutics PLC: Adaptimmune to Participate in Two Bank Conferences this SeptemberAugust 29, 2024 | americanbankingnews.comCritical Analysis: Protalix BioTherapeutics (NYSE:PLX) versus Adaptimmune Therapeutics (NASDAQ:ADAP)August 25, 2024 | marketbeat.comBaillie Gifford & Co. Reduces Position in Adaptimmune Therapeutics plc (NASDAQ:ADAP)Baillie Gifford & Co. trimmed its stake in Adaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) by 4.6% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,149,203 shares of the biotechnology company's sAugust 24, 2024 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) Shares Cross Above 50-Day Moving Average of $1.10Adaptimmune Therapeutics (NASDAQ:ADAP) Share Price Passes Above 50 Day Moving Average of $1.10August 16, 2024 | marketbeat.comShort Interest in Adaptimmune Therapeutics plc (NASDAQ:ADAP) Grows By 13.2%Adaptimmune Therapeutics plc (NASDAQ:ADAP - Get Free Report) saw a large growth in short interest in July. As of July 31st, there was short interest totalling 7,130,000 shares, a growth of 13.2% from the July 15th total of 6,300,000 shares. Based on an average daily volume of 2,030,000 shares, the short-interest ratio is currently 3.5 days.August 15, 2024 | markets.businessinsider.comHold Rating on Adaptimmune Amid Commercialization and Financial UncertaintiesAugust 15, 2024 | finance.yahoo.comAdaptimmune Therapeutics (NASDAQ:ADAP) investors are sitting on a loss of 74% if they invested three years agoAugust 15, 2024 | marketbeat.comAdaptimmune Therapeutics plc (NASDAQ:ADAP) to Post Q3 2024 Earnings of ($0.24) Per Share, HC Wainwright ForecastsAdaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) - Analysts at HC Wainwright dropped their Q3 2024 earnings per share estimates for shares of Adaptimmune Therapeutics in a research note issued to investors on Tuesday, August 13th. HC Wainwright analyst A. He now anticipates that the bioteAugust 13, 2024 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) Raised to Strong-Buy at StockNews.comStockNews.com raised shares of Adaptimmune Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Tuesday.August 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Adaptimmune Therapeutics Amidst Promising Product Launch and Strong PipelineAugust 13, 2024 | msn.comAdaptimmune Therapeutics plc (NASDAQ:ADAP) Q2 2024 Earnings Call TranscriptAugust 13, 2024 | marketbeat.comHC Wainwright Reiterates "Buy" Rating for Adaptimmune Therapeutics (NASDAQ:ADAP)HC Wainwright reissued a "buy" rating and set a $4.00 price objective on shares of Adaptimmune Therapeutics in a report on Tuesday.August 12, 2024 | markets.businessinsider.comBuy Rating Justified by Adaptimmune’s Promising Financials and Strong Product Launch ProspectsAugust 12, 2024 | seekingalpha.comAdaptimmune Therapeutics plc (ADAP) Q2 2024 Earnings Call TranscriptAugust 12, 2024 | markets.businessinsider.comADAP Stock Earnings: Adaptimmune Therapeutics Beats EPS, Beats Revenue for Q2 2024August 12, 2024 | finance.yahoo.comBP_CCB RP1911F (66756.HK)August 9, 2024 | finance.yahoo.comAdaptimmune leads in soft tissue sarcoma therapy with first TCR approvalAugust 8, 2024 | bizjournals.comSeed Therapeutics enters into collaboration deal valued at up to $1.5B with Japan-based EisaiAugust 7, 2024 | markets.businessinsider.comOutperform Rating Affirmed for Adaptimmune Following FDA Approval and Positive Market Outlook for TecelraAugust 6, 2024 | marketbeat.comAdaptimmune Therapeutics (ADAP) to Release Quarterly Earnings on MondayAdaptimmune Therapeutics (NASDAQ:ADAP) will be releasing earnings before the market opens on Monday, August 12, Zacks reports.August 5, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), Lantheus (LNTH) and Vertex Pharmaceuticals (VRTX)August 2, 2024 | msn.comAdaptimmune granted FDA accelerated nod for lead assetAugust 2, 2024 | msn.comFDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A DecadeAugust 2, 2024 | reuters.comUS FDA approves Adaptimmune's gene therapy for rare type of cancerAugust 1, 2024 | bizjournals.comAdaptimmune just days from potentially 'transformative' FDA ruling on its first solid tumor cell therapyAugust 1, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Teladoc (TDOC), SAGE Therapeutics (SAGE) and Herbalife (HLF)August 1, 2024 | marketbeat.comHC Wainwright Weighs in on Adaptimmune Therapeutics plc's Q2 2024 Earnings (NASDAQ:ADAP)Adaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) - Equities research analysts at HC Wainwright issued their Q2 2024 earnings estimates for shares of Adaptimmune Therapeutics in a research report issued to clients and investors on Tuesday, July 30th. HC Wainwright analyst A. He forecasts tJuly 31, 2024 | msn.comHC Wainwright & Co. Initiates Coverage of Adaptimmune Therapeutics plc - Depositary Receipt () (ADAP) with Buy RecommendationJuly 31, 2024 | msn.comHC Wainwright & Co. Initiates Coverage of Adaptimmune Therapeutics plc - Depositary Receipt () (ADAP) with Buy RecommendationJuly 30, 2024 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) Now Covered by Analysts at HC WainwrightHC Wainwright assumed coverage on shares of Adaptimmune Therapeutics in a research note on Tuesday. They issued a "buy" rating and a $4.00 price target for the company.July 25, 2024 | insidermonkey.comWhy Are Hedge Funds Bullish on Adaptimmune Therapeutics plc (ADAP) Now?July 19, 2024 | markets.businessinsider.comBuy Rating Affirmed for Adaptimmune on Revolutionary T-cell Therapy Prospects and Strong Sales ForecastJuly 15, 2024 | marketbeat.comAdaptimmune Therapeutics plc (NASDAQ:ADAP) Short Interest Up 15.1% in JuneAdaptimmune Therapeutics plc (NASDAQ:ADAP - Get Free Report) was the recipient of a large growth in short interest during the month of June. As of June 30th, there was short interest totalling 5,640,000 shares, a growth of 15.1% from the June 15th total of 4,900,000 shares. Based on an average daily trading volume, of 1,570,000 shares, the short-interest ratio is currently 3.6 days.July 3, 2024 | investorplace.com3 Biotech Moonshots With Imminent Catalyst PotentialJune 19, 2024 | insidertrades.comAdaptimmune Therapeutics plc (NASDAQ:ADAP) Insider Cintia Piccina Sells 24,531 SharesJune 18, 2024 | marketbeat.comCintia Piccina Sells 24,531 Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP) StockAdaptimmune Therapeutics plc (NASDAQ:ADAP - Get Free Report) insider Cintia Piccina sold 24,531 shares of Adaptimmune Therapeutics stock in a transaction dated Tuesday, June 18th. The shares were sold at an average price of $0.93, for a total value of $22,813.83. Following the sale, the insider now directly owns 38,293 shares in the company, valued at $35,612.49. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.May 30, 2024 | globenewswire.comGalapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indicationsMay 29, 2024 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) Stock Price Passes Below 50-Day Moving Average of $1.21Adaptimmune Therapeutics (NASDAQ:ADAP) Stock Passes Below 50 Day Moving Average of $1.21May 23, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Cooper Co (COO), Neurocrine (NBIX) and Arcturus Therapeutics (ARCT)May 20, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Start Week Marginally Higher in Monday TradingMay 17, 2024 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) PT Lowered to $3.00 at MizuhoMizuho cut their target price on shares of Adaptimmune Therapeutics from $9.00 to $3.00 and set a "buy" rating on the stock in a research report on Friday.May 17, 2024 | marketbeat.comLeerink Partnrs Weighs in on Adaptimmune Therapeutics plc's Q2 2024 Earnings (NASDAQ:ADAP)Adaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) - Equities research analysts at Leerink Partnrs decreased their Q2 2024 earnings per share estimates for Adaptimmune Therapeutics in a research report issued to clients and investors on Wednesday, May 15th. Leerink Partnrs analyst J. ChangMay 16, 2024 | msn.comAdaptimmune Therapeutics plc (NASDAQ:ADAP) Q1 2024 Earnings Call TranscriptMay 15, 2024 | investorplace.comADAP Stock Earnings: Adaptimmune Therapeutics Misses EPS, Misses Revenue for Q1 2024May 14, 2024 | msn.comAdaptimmune Q1 2024 Earnings PreviewMay 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: ANI Pharmaceuticals (ANIP), Fate Therapeutics (FATE) and Instil Bio (TIL)May 10, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Aclaris Therapeutics (ACRS) and Immunocore Holdings (IMCR)April 29, 2024 | finance.yahoo.comGlobal CD70 Targeting Therapies Market & Clinical Trials Report 2024 - Insight by Company, Country, Indication & PhaseApril 26, 2024 | seekingalpha.comAdaptimmune: Huge Opportunity Amid Their Setback With GenentechApril 26, 2024 | bizjournals.comGenentech parent Roche has cut 20% of risky drugs from pipeline and is adjusting its workforce to match Get Adaptimmune Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter. Email Address Perfect Crypto Buying Opportunity for 50 Cents (Ad)When cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying with both fists. They know it's only a matter of time before another bull run. Now, Crypto Insiders Are Scooping up Lesser-Known Coins and Making Serious Bank Go here to get full details on this crypto now. ADAP Media Mentions By Week ADAP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ADAP News Sentiment▼0.000.55▲Average Medical News Sentiment ADAP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ADAP Articles This Week▼02▲ADAP Articles Average Week Get Adaptimmune Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PGEN News FATE News CLLS News BLUE News ATRA News IRON News ARQT News TNGX News NRIX News CALT News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ADAP) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptimmune Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptimmune Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
